Please login to the form below

Not currently logged in
Email:
Password:

veno-occlusive disease

This page shows the latest veno-occlusive disease news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Pfizer's antibody drug for leukaemia

NICE rejects Pfizer's antibody drug for leukaemia

After the publication of the INO-VATE data oncologists welcomed having an alternative that is generally easier to tolerate than chemo, although Besponsa has been linked to veno-occlusive disease (VOD)

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... The US regulator has approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    The Italy-based pharma company had applied for European approval of defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation therapy,

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    3, 080. Cosmo Technologies/ Salix Pharmaceuticals. Merger (tax inversion)    . Portfolio of treatments for gastrointestinal disease and disorders. ... 360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics